首页> 美国政府科技报告 >Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers.

【24h】

Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers.

机译：缺乏BIm表达作为EGFR-突变和aLK阳性肺癌中靶向疗法的内在和获得性抗性的机制。

获取原文

页面导航

著录项
相似文献
相关主题

著录项

作者
Engelman, J.; Sequist, L.;
展开▼
作者单位

展开▼
年度 2016
页码 1-27
总页数 27
原文格式 PDF
正文语种 eng
中图分类
关键词
Apoptosis; Cell lines; Medical research; Biopsy; Therapeutics; Drug resistance; Lung cancer;

机译：细胞凋亡;细胞系;医学研究;活组织检查;治疗学;耐药性;肺癌;

相似文献

外文文献
中文文献
专利

1. Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin [J] . Corominas-FajaB., Oliveras-FerrarosC., CuyàsE., Cell cycle . 2013,第21期

机译：EGFR突变型非小细胞肺癌中的干细胞样ALDH亮细胞状态是天然多酚水飞蓟宾可靶向的对厄洛替尼获得性耐药的新机制
2. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies [J] . Bagrodia S., Smeal T., Abraham R.T. Pigment cell & melanoma research . 2012,第6期

机译：对激酶靶向疗法的内在和获得性耐药机制
3. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies [J] . Lim Sun Min, Syn Nicholas L., Cho Byoung Chul, Cancer Treatment Reviews . 2018,第期

机译：获得非小细胞肺癌eGFR靶向治疗的抗性：机制和治疗策略
4. Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA [C] . Cloud P. Paweletz, Geoffrey R. Oxnard, Yanan Kuang, Molecular Medicine TRI-CON. . 2014

机译：无细胞血浆DNA定量下一代基因分型非富集突变体肺癌响应和抗性的非侵袭性检测
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications [O] . Brent N. Rexer, Carlos L. Arteaga -1

机译：在HER2基因扩增的乳腺癌中的内在和获得抗HER2靶向疗法的抵抗力：机制和临床意义
7. Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications [O] . Brent N. Rexer, Carlos L. Arteaga 2012

机译：在HER2基因扩增的乳腺癌中的内在和获得抗HER2靶向疗法的抵抗力：机制和临床意义
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2014

机译：缺乏BIm表达作为EGFR-突变和aLK阳性肺癌中靶向疗法的内在和获得性抗性的机制。

Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers.

著录项

相似文献

相关主题

期刊订阅